- Home
- SLRX
SLRX
Salarius Pharmaceuticals Inc.
as 04-24-2025 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 267.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $7.20 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Salarius Pharmaceuticals Inc. News
SLRX Breaking Stock News: Dive into SLRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
GlobeNewswire
a month ago
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
GlobeNewswire
a month ago
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
MT Newswires
3 months ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
3 months ago
Sector Update: Health Care
MT Newswires
3 months ago
Top Midday Gainers
MT Newswires
3 months ago
Salarius Pharma Shares More than Double on Merger Deal With Decoy Therapeutics
Compare SLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRX Salarius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.